Total Revenue: $244.3 million, up 19% year over year. DAYBUE Sales: $84.6 million, up 11% year over year. NUPLAZID Sales: $159.7 million, up 23% year over year, with 6% growth from volume. R&D Expenses: $78.3 million, up from $59.7 million in Q1 2024. SG&A Expenses: $126.4 million, up from $108 million in Q1 2024. Cash Balance: $681.6 million as of March 31. Unique Patients for DAYBUE: 954, an all-time record for the brand. Gross-to-Net Adjustment for DAYBUE: 24.9%. Gross-to-Net Adjustment for NUPLAZID: 24.1%. 2025 R&D Expense Guidance: Increased to $330 million to $350 million.

Warning! GuruFocus has detected 4 Warning Sign with ACAD.

Release Date: May 07, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) reported a strong first quarter with total revenues of $244.3 million, up 19% year-over-year. DAYBUE sales reached $84.6 million, marking an 11% increase from the previous year, with a record number of 954 unique patients receiving shipments. NUPLAZID achieved $159.7 million in revenue for the quarter, representing a 23% increase year-over-year, driven by a 6% growth in volume. The company is on track to complete enrollment for the COMPASS PWS Phase 3 study in Prader-Willi Syndrome, with top-line results expected by the end of 2025. ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) has expanded its field force for DAYBUE and initiated managed access programs in Europe, laying the groundwork for a strong international launch.

Negative Points

DAYBUE sales were down sequentially due to factors like seasonality and Medicare Part D redesign impacting net price. R&D expenses increased to $78.3 million, up from $59.7 million in the first quarter of 2024, due to higher spending on clinical-stage programs. SG&A expenses rose to $126.4 million, driven by NUPLAZID consumer activation campaigns and commercial operation expenses. The company is winding down efforts for certain discovery programs in collaboration with Stoke Therapeutics, indicating challenges in those areas. Persistency for DAYBUE remains around 50% after 12 months, suggesting room for improvement in long-term patient retention.

Q & A Highlights

Q: What does good data for ACP-101 look like, and how does it relate to discussions with the FDA? Also, how should we model European pricing for DAYBUE considering potential pricing risks? A: Elizabeth Thompson, EVP, Head of R&D, stated that a statistically significant result in the ACP-101 trial would demonstrate a clinically meaningful impact on hyperphagia, a key symptom of Prader-Willi Syndrome. Catherine Owen Adams, CEO, mentioned that while modeling European pricing for DAYBUE, they are confident in obtaining a strong EU price that reflects the value provided to patients, despite potential pricing risks.

Story Continues

Q: What should we expect in terms of sequential growth for NUPLAZID and DAYBUE from Q1 to Q2? A: Thomas Garner, Chief Commercial Officer, explained that for DAYBUE, the expanded customer model will impact Q2, with significant growth potential outside of Centers of Excellence. For NUPLAZID, the focus remains on leveraging unbranded and branded campaigns to drive growth. Mark Schneyer, CFO, added that volume will be the primary growth driver for both brands, with DAYBUE benefiting from Medicaid pricing adjustments.

Q: How confident are you in the low dose of carbetocin for Prader-Willi Syndrome, and what are your thoughts on GLP-1 use in this condition? A: Elizabeth Thompson, EVP, Head of R&D, expressed confidence in the 3.2-milligram dose of carbetocin, citing mechanistic relevance and internal consistency in prior data. Regarding GLP-1, she noted that while there is some use in Prader-Willi, definitive studies are lacking, and the jury is still out on its effectiveness.

Q: Are there any phenotypic behaviors or patient subsets more likely to respond to treatment in the COMPASS trial? A: Elizabeth Thompson, EVP, Head of R&D, stated that based on current data, no specific patient subsets have been identified as more likely to respond to carbetocin. More information will be available from the ongoing COMPASS trial.

Q: What are the biggest risks to trofinetide's approval process in the EU, and how does business development fit into your priorities? A: Catherine Owen Adams, CEO, expressed confidence in the EMA approval process for trofinetide, with no indications of deviation from the expected timeline. Regarding business development, she emphasized a focus on acquiring assets in areas of high medical need, with a disciplined approach to financial management.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments